EP1479358A1 - Enhanced radiopacity intraluminal device - Google Patents

Enhanced radiopacity intraluminal device Download PDF

Info

Publication number
EP1479358A1
EP1479358A1 EP04252955A EP04252955A EP1479358A1 EP 1479358 A1 EP1479358 A1 EP 1479358A1 EP 04252955 A EP04252955 A EP 04252955A EP 04252955 A EP04252955 A EP 04252955A EP 1479358 A1 EP1479358 A1 EP 1479358A1
Authority
EP
European Patent Office
Prior art keywords
stent
marker
stents
markers
alloy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04252955A
Other languages
German (de)
French (fr)
Inventor
Alan Pelton
Thomas Duerig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cordis Corp
Original Assignee
Cordis Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cordis Corp filed Critical Cordis Corp
Publication of EP1479358A1 publication Critical patent/EP1479358A1/en
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/90Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
    • A61F2/91Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/90Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
    • A61F2/91Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
    • A61F2/915Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/02Inorganic materials
    • A61L31/022Metals or alloys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/18Materials at least partially X-ray or laser opaque
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B90/00Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
    • A61B90/39Markers, e.g. radio-opaque or breast lesions markers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/90Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
    • A61F2/91Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
    • A61F2/915Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
    • A61F2002/91533Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other characterised by the phase between adjacent bands
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/90Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
    • A61F2/91Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
    • A61F2/915Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
    • A61F2002/9155Adjacent bands being connected to each other
    • A61F2002/91558Adjacent bands being connected to each other connected peak to peak
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2230/00Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2230/0002Two-dimensional shapes, e.g. cross-sections
    • A61F2230/0028Shapes in the form of latin or greek characters
    • A61F2230/005Rosette-shaped, e.g. star-shaped
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2230/00Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2230/0002Two-dimensional shapes, e.g. cross-sections
    • A61F2230/0028Shapes in the form of latin or greek characters
    • A61F2230/0054V-shaped
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0096Markers and sensors for detecting a position or changes of a position of an implant, e.g. RF sensors, ultrasound markers
    • A61F2250/0098Markers and sensors for detecting a position or changes of a position of an implant, e.g. RF sensors, ultrasound markers radio-opaque, e.g. radio-opaque markers

Definitions

  • the present invention relates to intraluminal devices, and more particularly to intraluminal devices, such as stents, incorporating integral markers for increasing the radiopacity thereof.
  • the present invention also relates to intraluminal devices formed from higher radiopacity alloys.
  • Percutaneous transluminal angioplasty is a therapeutic medical procedure used to increase blood flow through an artery.
  • the angioplasty balloon is inflated within the stenosed vessel, or body passageway, in order to shear and disrupt the wall components of the vessel to obtain an enlarged lumen.
  • the relatively incompressible plaque remains unaltered, while the more elastic medial and adventitial layers of the body passageway stretch around the plaque. This process produces dissection, or a splitting and tearing, of the body passageway wall layers, wherein the intima, or internal surface of the artery or body passageway, suffers fissuring.
  • This dissection forms a "flap" of underlying tissue which may reduce the blood flow through the lumen, or completely block the lumen.
  • the distending intraluminal pressure within the body passageway can hold the disrupted layer, or flap, in place. If the intimal flap created by the balloon dilation procedure is not maintained in place against the expanded intima, the intimal flap can fold down into the lumen and close off the lumen, or may even become detached and enter the body passageway. When the intimal flap closes off the body passageway, immediate surgery is necessary to correct the problem.
  • transluminal prostheses have been widely used in the medical arts for implantation in blood vessels, biliary ducts, or other similar organs of the living body. These prostheses are commonly referred to as stents and are used to maintain, open, or dilate tubular structures.
  • An example of a commonly used stent is given in U.S. Patent No. 4,733,665 to Palmaz.
  • Such stents are often referred to as balloon expandable stents.
  • the stent is made from a solid tube of stainless steel. Thereafter, a series of cuts are made in the wall of the stent.
  • the stent has a first smaller diameter which permits the stent to be delivered through the human vasculature by being crimped onto a balloon catheter.
  • the stent also has a second, expanded diameter, upon application of a radially, outwardly directed force, by the balloon catheter, from the interior of the tubular shaped member.
  • stents are often impractical for use in some vessels such as the carotid artery.
  • the carotid artery is easily accessible from the exterior of the human body, and is close to the surface of the skin.
  • a patient having a balloon expandable stent made from stainless steel or the like, placed in their carotid artery might be susceptible to severe injury through day to day activity. A sufficient force placed on the patient's neck could cause the stent to collapse, resulting in injury to the patient.
  • self-expanding stents have been proposed for use in such vessels. Self-expanding stents act like springs and will recover to their expanded or implanted configuration after being crushed.
  • U.S. Patent No. 4,655,771 One type of self-expanding stent is disclosed in U.S. Patent No. 4,655,771.
  • the stent disclosed in U.S. Patent No. 4,655,771 has a radially and axially flexible, elastic tubular body with a predetermined diameter that is variable under axial movement of the ends of the body relative to each other and which is composed of a plurality of individually rigid but flexible and elastic thread elements defining a radially self-expanding helix.
  • This type of stent is known in the art as a "braided stent" and is so designated herein. Placement of such stents in a body vessel can be achieved by a device which comprises an outer catheter for holding the stent at its distal end, and an inner piston which pushes the stent forward once it is in position.
  • braided stents have many disadvantages. They typically do not have the necessary radial strength to effectively hold open a diseased vessel.
  • the plurality of wires or fibers used to make such stents could become dangerous if separated from the body of the stent, where they could pierce through the vessel. Therefore, there has been a desire to have a self-expanding stent which is cut from a tube of metal, which is the common manufacturing method for many commercially available balloon-expandable stents.
  • the alloy used In order to manufacture a self-expanding stent cut from a tube, the alloy used would preferably exhibit superelastic or psuedoelastic characteristics at body temperature, so that it is crush recoverable.
  • the prior art makes reference to the use of alloys such as Nitinol (Ni Ti alloy), which have shape memory and/or superelastic characteristics, in medical devices which are designed to be inserted into a patient's body.
  • the shape memory characteristics allow the devices to be deformed to facilitate their insertion into a body lumen or cavity and then be heated within the body so that the device returns to its original shape.
  • Superelastic characteristics generally allow the metal to be deformed and restrained in the deformed condition to facilitate the insertion of the medical device containing the metal into a patient's body, with such deformation causing the phase transformation. Once within the body lumen, the restraint on the superelastic member can be removed, thereby reducing the stress therein so that the superelastic member can return to its original un-deformed shape by the transformation back to the original phase.
  • Alloys having shape memory/superelastic characteristics generally have at least two phases. These phases are a martensite phase, which has a relatively low tensile strength and which is stable at relatively low temperatures, and an austenite phase, which has a relatively high tensile strength and which is stable at temperatures higher than the martensite phase.
  • Shape memory characteristics are imparted to the alloy by heating the metal at a temperature above which the transformation from the martensite phase to the austenite phase is complete, i.e. a temperature above which the austenite phase is stable (the Af temperature).
  • the shape of the metal during this heat treatment is the shape "remembered.”
  • the heat-treated metal is cooled to a temperature at which the martensite phase is stable, causing the austenite phase to transform to the martensite phase.
  • the metal in the martensite phase is then plastically deformed, e.g. to facilitate the entry thereof into a patient's body.
  • the specimen When stress is applied to a specimen of a metal such as Nitinol exhibiting superelastic characteristics at a temperature above which the austenite is stable (i.e. the temperature at which the transformation of martensite phase to the austenite phase is complete), the specimen deforms elastically until it reaches a particular stress level where the alloy then undergoes a stress induced phase transformation from the austenite phase to the martensite phase. As the phase transformation proceeds, the alloy undergoes significant increases in strain but with little or no corresponding increases in stress. The strain increases while the stress remains essentially constant until the transformation of the austenite phase to the martensite phase is complete. Thereafter, further increases in stress are necessary to cause further deformation. The martensitic metal first deforms elastically upon the application of additional stress and then plastically with permanent residual deformation.
  • a metal such as Nitinol exhibiting superelastic characteristics at a temperature above which the austenite is stable (i.e. the temperature at which the transformation of martensite phase to
  • the martensitic specimen will elastically recover and transform back to the austenite phase.
  • the reduction in stress first causes a decrease in strain.
  • stress reduction reaches the level at which the martensite phase transforms back into the austenite phase
  • the stress level in the specimen will remain essentially constant (but substantially less than the constant stress level at which the austenite transforms to the martensite) until the transformation back to the austenite phase is complete, i.e. there is significant recovery in strain with only negligible corresponding stress reduction.
  • further stress reduction results in elastic strain reduction.
  • the prior art makes reference to the use of metal alloys having superelastic characteristics in medical devices which are intended to be inserted or otherwise used within a patient's body. See for example, U.S. Patent No. 4,665,905 to Jervis and U.S. Patent No. 4,925,445 to Sakamoto et al.
  • the prior art has yet to disclose any suitable tube-cut self-expanding stents.
  • many of the prior art stents lacked the necessary rigidity or hoop strength to keep the body vessel open.
  • many of the prior art stents have large openings at their expanded diameter. The smaller the openings are on an expanded stent, the more plaque or other deposits it can trap between the stent and the vessel wall. Trapping these deposits is important to the continuing health of the patient in that it helps prevent plaque prolapse into the vessel, restenosis of the vessel it is implanted into, and strokes caused by the release of embolic particles into the bloodstream.
  • markers made from highly radiopaque materials
  • Those materials typically include gold, platinum, or tantalum.
  • the prior art makes reference to these markers or processes in U.S. Patent No. 5,632,771 to Boatman et al., U.S. Patent No. 6,022,374 to Imran, U.S. Patent No. 5,741,327 to Frantzen, U.S. Patent No. 5,725,572 to Lam et al., and U.S. Patent No.
  • the present invention overcomes many of the disadvantages associated with reduced radiopacity exhibited by self-expanding stents, balloon-expandable stents, and other medical devices as briefly discussed above.
  • the present invention is directed to an intraluminal medical device.
  • the intraluminal medical device comprises a substantially tubular member having open ends, a first diameter for insertion into a lumen of a vessel and a second diameter for anchoring in the lumen of the vessel.
  • the substantially tubular member comprising an alloy including nickel, titanium and a metal having a radiopacity greater than nickel or titanium.
  • the improved radiopacity intraluminal medical device of the present invention utilizes high radiopacity markers to ensure proper positioning of the device within a lumen.
  • the markers comprise a housing which is integral to the device itself, thereby ensuring minimal interference with deployment and operation of the device.
  • the housings are also shaped to minimally impact the overall profile of the stent. For example, a properly shaped housing allows a stent to maintain a radiopaque stent marker size utilized in a seven French delivery system to fit into a six French delivery system.
  • the markers also comprise a properly sized marker insert having a higher radiopacity than the material forming the device itself.
  • the marker insert is sized to match the curvature of the housing thereby ensuring a tight and unobtrusive fit.
  • the marker inserts are made from a material close in the galvanic series to the device material and sized to substantially minimize the effect of galvanic corrosion.
  • the improved radiopacity intraluminal medical device of the present invention provides for more precise placement and post-procedural visualization in a lumen by increasing the radiopacity of the device under X-ray fluoroscopy.
  • the marker housings are integral to the device, they are simpler and less expensive to manufacture than markers that have to be attached in a separate process.
  • the improved radiopacity intraluminal medical device of the present invention is manufactured utilizing a process which ensures that the marker insert is securely positioned within the marker housing.
  • the marker housing is laser cut from the same tube and is integral to the device.
  • the hole in the marker housing is conical in the radial direction with the outer surface diameter being larger than the inner surface diameter.
  • the conical tapering effect in the marker housing is beneficial in providing an interference fit between the marker insert and the marker housing to prevent the marker insert from being dislodged once the device is deployed.
  • the marker inserts are loaded into a crimped device by punching a disk from annealed ribbon stock and shaping it to have the same radius of curvature as the marker housing.
  • a coining process is used to properly seat the marker below the surface of the housing.
  • the coining punch is also shaped to maintain the same radius of curvature as the marker housing. The coining process deforms the marker housing material to form a protrusion, thereby locking in the insert or disk.
  • the improved radiopacity intraluminal medical device of the present invention may comprise an alloy of nickel, titanium and other suitable material or materials having higher radiopacities than the nickel and titanium.
  • Two such compatible materials include platinum and palladium. The addition of these materials will increase the radiopacity of the medical device and may reduce the need for additional markers.
  • FIG. 1 and 2 a stent 100, which may be utilized in connection with the present invention.
  • Figures 1 and 2 illustrate the exemplary stent 100 in its unexpanded or compressed state.
  • the stent 100 is preferably made from a superelastic alloy such as Nitinol.
  • the stent 100 is made from an alloy comprising from about 50.0 percent (as used herein these percentages refer to weight percentages) Ni to about 60 percent Ni, and more preferably about 55.8 percent Ni, with the remainder of the alloy being Ti.
  • the stent 100 is designed such that it is superelastic at body temperature, and preferably has an Af in the range from about twenty-four degrees C to about thirty-seven degrees C. The superelastic design of the stent 100 makes it crush recoverable, which, as discussed above, makes it useful as a stent or frame for any number of vascular devices in different applications.
  • Stent 100 is a tubular member having front and back open ends 102 and 104 and a longitudinal axis 106 extending therebetween.
  • the tubular member has a first smaller diameter, Figures 1 and 2, for insertion into a patient and navigation through the vessels, and a second larger diameter, Figures 3 and 4, for deployment into the target area of a vessel.
  • the tubular member is made from a plurality of adjacent hoops 108, Figure 1 showing hoops 108(a) - 108(d), extending between the front and back ends 102 and 104.
  • the hoops 108 include a plurality of longitudinal struts 110 and a plurality of loops 112 connecting adjacent struts, wherein adjacent struts are connected at opposite ends so as to form a substantially S or Z shape pattern.
  • the loops 112 are curved, substantially semi-circular with symmetrical sections about their centers 114.
  • Stent 100 further includes a plurality of bridges 116 which connect adjacent hoops 108 and which can best be described in detail by referring to Figure 5.
  • Each bridge 116 has two ends 118 and 120.
  • the bridges 116 have one end attached to one strut and/or loop, and another end attached to a strut and/or loop on an adjacent hoop.
  • the bridges 116 connect adjacent struts together at bridge to loop connection points 122 and 124.
  • bridge end 118 is connected to loop 114(a) at bridge to loop connection point 122
  • bridge end 120 is connected to loop 114(b) at bridge to loop connection point 124.
  • Each bridge to loop connection point has a center 126.
  • the bridge to loop connection points are separated angularly with respect to the longitudinal axis. That is, the connection points are not immediately opposite each other. Essentially, one could not draw a straight line between the connection points, wherein such line would be parallel to the longitudinal axis of the stent.
  • the above described geometry helps to better distribute strain throughout the stent, prevents metal to metal contact when the stent is bent, and minimizes the opening size between the struts, loops and bridges.
  • the number of and nature of the design of the struts, loops and bridges are important factors when determining the working properties and fatigue life properties of the stent. It was previously thought that in order to improve the rigidity of the stent, that struts should be large, and therefore there should be fewer struts per hoop. However, it has now been discovered that stents having smaller struts and more struts per hoop actually improve the construction of the stent and provide greater rigidity.
  • each hoop has between twenty-four to thirty-six or more struts. It has been determined that a stent having a ratio of number of struts per hoop to strut length L (in inches) which is greater than four hundred has increased rigidity over prior art stents, which typically have a ratio of under two hundred. The length of a strut is measured in its compressed state parallel to the longitudinal axis 106 of the stent 100 as illustrated in Figure 1.
  • the geometry of the stent 100 changes quite significantly as the stent 100 is deployed from its un-expanded state to its expanded state.
  • the strut angle and strain levels in the loops and bridges are affected.
  • all of the stent features will strain in a predictable manor so that the stent is reliable and uniform in strength.
  • the stent sits in the delivery system in its un-expanded state as shown in Figures 10 and 11.
  • Nitinol stents made from wire deploy in much the same manner, and are dependent upon the same design constraints, as laser cut stents.
  • Stainless steel stents deploy similarly in terms of geometric changes as they are assisted by forces from balloons or other devices.
  • the present invention utilizes structural geometries which distribute strain to areas of the stent which are less susceptible to failure than others.
  • one of the most vulnerable areas of the stent is the inside radius of the connecting loops.
  • the connecting loops undergo the most deformation of all the stent features.
  • the inside radius of the loop would normally be the area with the highest level of strain on the stent. This area is also critical in that it is usually the smallest radius on the stent.
  • Stress concentrations are generally controlled or minimized by maintaining the largest radii possible.
  • One way to accomplish this is to utilize the largest possible radii while maintaining feature widths which are consistent with applied forces.
  • Another consideration is to minimize the maximum open area of the stent. Efficient utilization of the original tube from which the stent is cut increases stent strength and its ability to trap embolic material.
  • This feature allows for maximum utilization of Ni-Ti or other material properties to enhance radial strength, to improve stent strength uniformity, to improve fatigue life by minimizing local strain levels, to allow for smaller open areas which enhance entrapment of embolic material, and to improve stent apposition in irregular vessel wall shapes and curves.
  • stent 100 comprises strut connecting loops 112 having a width W1, as measured at the center 114 parallel to axis 106, which are greater than the strut widths W2, as measured perpendicular to axis 106 itself.
  • the thickness of the loops vary so that they are thickest near their centers. This increases strain deformation at the strut and reduces the maximum strain levels at the extreme radii of the loop. This reduces the risk of stent failure and allows one to maximize radial strength properties. This feature is particularly advantageous for stents having large expansion ratios, which in turn requires them to have extreme bending requirements where large elastic strains are required.
  • Nitinol can withstand extremely large amounts of elastic strain deformation, so the above features are well suited to stents made from this alloy. As stated above, this feature allows for maximum utilization of Ni-Ti or other material properties to enhance radial strength, to improve stent strength uniformity, to improve fatigue life by minimizing local strain levels, to allow for smaller open areas which enhance entrapment of embolic material, and to improve stent apposition in irregular vessel wall shapes and curves.
  • bridge geometry changes as a stent is deployed from its compressed state to its expanded state and vise-versa.
  • strut angle and loop strain is affected. Since the bridges are connected to either the loops, struts or both, they are affected. Twisting of one end of the stent with respect to the other, while loaded in the stent delivery system, should be avoided. Local torque delivered to the bridge ends displaces the bridge geometry. If the bridge design is duplicated around the stent perimeter, this displacement causes rotational shifting of the two loops being connected by the bridges. If the bridge design is duplicated throughout the stent, as in the present invention, this shift will occur down the length of the stent.
  • a stent delivery system such as the one described below, will deploy the distal end first, then allow the proximal end to expand. It would be undesirable to allow the distal end to anchor into the vessel wall while holding the stent fixed in rotation, then release the proximal end. This could cause the stent to twist or whip in rotation to equilibrium after it is at least partially deployed within the vessel. Such whipping action may cause damage to the vessel.
  • one exemplary embodiment of the present invention reduces the chance of such events happening when deploying the stent.
  • the rotational shift of the Z-sections or S-sections may be made to alternate and will minimize large rotational changes between any two points on a given stent during deployment or constraint. That is, the bridges 116 connecting loop 108(b) to loop 108(c) are angled upwardly from left to right, while the bridges connecting loop 108(c) to loop 108(d) are angled downwardly from left to right. This alternating pattern is repeated down the length of the stent 100.
  • This alternating pattern of bridge slopes improves the torsional characteristics of the stent so as to minimize any twisting or rotation of the stent with respect to any two hoops.
  • This alternating bridge slope is particularly beneficial if the stent starts to twist in vivo. As the stent twists, the diameter of the stent will change. Alternating bridge slopes tend to minimize this effect. The diameter of a stent having bridges which are all sloped in the same direction will tend to grow if twisted in one direction and shrink if twisted in the other direction. With alternating bridge slopes this effect is minimized and localized.
  • Nitinol as stated above, can withstand extremely large amounts of elastic strain deformation, so the above features are well suited to stents made from this alloy.
  • This feature allows for maximum utilization of Ni-Ti or other material properties to enhance radial strength, to improve stent strength uniformity, to improve fatigue life by minimizing local strain levels, to allow for smaller open areas which enhance entrapment of embolic material, and to improve stent apposition in irregular vessel wall shapes and curves.
  • stents are laser cut from small diameter tubing.
  • this manufacturing process led to designs with geometric features, such as struts, loops and bridges, having axial widths W2, W1 and W3, respectively, which are larger than the tube wall thickness T (illustrated in Figure 3).
  • struts, loops and bridges having axial widths W2, W1 and W3, respectively, which are larger than the tube wall thickness T (illustrated in Figure 3).
  • This feature allows for maximum utilization of Ni-Ti or other material properties to enhance radial strength, to improve stent strength uniformity, to improve fatigue life by minimizing local strain levels, to allow for smaller open areas which enhance entrapment of embolic material, and to improve stent apposition in irregular vessel wall shapes and curves.
  • FIG. 6 shows stent 200 which is similar to stent 100 illustrated in Figures 1-5.
  • Stent 200 is made from a plurality of adjacent hoops 202, Figure 6 showing hoops 202(a) - 202(d).
  • the hoops 202 include a plurality of longitudinal struts 204 and a plurality of loops 206 connecting adjacent struts, wherein adjacent struts are connected at opposite ends so as to form a substantially S or Z shape pattern.
  • Stent 200 further includes a plurality of bridges 208 which connect adjacent hoops 202. As seen from the figure, bridges 208 are non-linear and curve between adjacent hoops.
  • the stent of the present invention be made from a superelastic alloy and most preferably made of an alloy material having greater than 50.5 atomic percentage Nickel and the balance Titanium. Greater than 50.5 atomic percentage Nickel allows for an alloy in which the temperature at which the martensite phase transforms completely to the austenite phase (the Af temperature) is below human body temperature, and preferably is about twenty-four degrees C to about thirty-seven degrees C, so that austenite is the only stable phase at body temperature.
  • Nitinol tubing is commercially available from a number of suppliers including Nitinol Devices and Components, Fremont CA.
  • the tubular member is then loaded into a machine which will cut the predetermined pattern of the stent into the tube, as discussed above and as shown in the figures.
  • Machines for cutting patterns in tubular devices to make stents or the like are well known to those of ordinary skill in the art and are commercially available.
  • Such machines typically hold the metal tube between the open ends while a cutting laser, preferably under microprocessor control, cuts the pattern.
  • the pattern dimensions and styles, laser positioning requirements, and other information are programmed into a microprocessor which controls all aspects of the process.
  • the stent pattern is cut, the stent is treated and polished using any number of methods or combination of methods well known to those skilled in the art. Lastly, the stent is then cooled until it is completely martensitic, crimped down to its un-expanded diameter and then loaded into the sheath of the delivery apparatus.
  • markers having a radiopacity greater than that of the superelastic alloys may be utilized to facilitate more precise placement of the stent within the vasculature.
  • markers may be utilized to determine when and if a stent is fully deployed. For example, by determining the spacing between the markers, one can determine if the deployed stent has achieved its maximum diameter and adjusted accordingly utilizing a tacking process.
  • Figure 7 illustrates an exemplary embodiment of the stent 100 illustrated in Figures 1-5 having at least one marker on each end thereof.
  • a stent having thirty-six struts per hoop can accommodate six markers 800.
  • Each marker 800 comprises a marker housing 802 and a marker insert 804.
  • the marker insert 804 may be formed from any suitable biocompatible material having a high radiopacity under X-ray fluoroscopy. In other words, the marker inserts 804 should preferably have a radiopacity higher than that of the material comprising the stent 100.
  • the addition of the marker housings 802 to the stent necessitates that the lengths of the struts in the last two hoops at each end of the stent 100 be longer than the strut lengths in the body of the stent to increase the fatigue life at the stent ends.
  • the marker housings 802 are preferably cut from the same tube as the stent as briefly described above. Accordingly, the housings 802 are integral to the stent 100. Having the housings 802 integral to the stent 100 serves to ensure that the markers 800 do not interfere with the operation of the stent
  • Figure 8 is a cross-sectional view of a marker housing 802.
  • the housing 802 may be elliptical when observed from the outer surface as illustrated in Figure 7.
  • the hole 806 in the marker housing 802 is conical in the radial direction with the outer surface 808 having a diameter larger than the diameter of the inner surface 810, as illustrated in Figure 8.
  • the conical tapering in the marker housing 802 is beneficial in providing an interference fit between the marker insert 804 and the marker housing 802 to prevent the marker insert 804 from being dislodged once the stent 100 is deployed. A detailed description of the process of locking the marker insert 804 into the marker housing 802 is given below.
  • the marker inserts 804 may be made from any suitable material having a radiopacity higher than the superelastic material forming the stent or other medical device.
  • the marker insert 804 may be formed from niobium, tungsten, gold, platinum or tantalum.
  • tantalum is utilized because of its closeness to nickel-titanium in the galvanic series and thus would minimize galvanic corrosion.
  • the surface area ratio of the tantalum marker inserts 804 to the nickel-titanium is optimized to provide the largest possible tantalum marker insert, easy to see, while minimizing the galvanic corrosion potential.
  • marker inserts 804 having a diameter of 0.254 mm (0.010 inches) could be placed at the end of the stent 100; however, these marker inserts 804 would be less visible under X-ray fluoroscopy.
  • three to four marker inserts 804 having a diameter of 0.635 mm (0.025 inches) could be accommodated on the stent 100; however, galvanic corrosion resistance would be compromised.
  • six tantalum markers having a diameter of 0.508 mm (0.020 inches) are utilized on each end of the stent 100 for a total of twelve markers 800.
  • the tantalum markers 804 may be manufactured and loaded into the housing utilizing a variety of known techniques.
  • the tantalum markers 804 are punched out from an annealed ribbon stock and are shaped to have the same curvature as the radius of the marker housing 802 as illustrated in Figure 8.
  • a coining process is used to properly seat the marker insert 804 below the surface of the housing 802.
  • the coining punch is also shaped to maintain the same radius of curvature as the marker housing 802. As illustrated in Figure 8, the coining process deforms the marker housing 802 material to lock in the marker insert 804.
  • the hole 806 in the marker housing 802 is conical in the radial direction with the outer surface 808 having a diameter larger than the diameter of the inner surface 810 as illustrated in Figure 8.
  • the inside and outside diameters vary depending on the radius of the tube from which the stent is cut.
  • the marker inserts 804, as stated above, are formed by punching a tantalum disk from annealed ribbon stock and shaping it to have the same radius of curvature as the marker housing 802. It is important to note that the marker inserts 804, prior to positioning in the marker housing 804, have straight edges. In other words, they are not angled to match the hole 806.
  • the diameter of the marker insert 804 is between the inside and outside diameter of the marker housing 802.
  • the thickness of the marker insert 804 is less than or equal to the thickness of the tubing and thus the thickness or height of the hole 806. Accordingly, by applying the proper pressure during the coining process and using a coining tool that is larger than the marker insert 804, the marker insert 804 may be seated in the marker housing 802 in such a way that it is locked into position by a radially oriented protrusion 812. Essentially, the applied pressure, and size and shape of the housing tool forces the marker insert 804 to form the protrusion 812 in the marker housing 802.
  • the coining tool is also shaped to maintain the same radius of curvature as the marker housing 802. As illustrated in Figure 8, the protrusion 812 prevents the marker insert 804 from becoming dislodged from the marker housing 802.
  • the marker inserts 804 are positioned in and locked into the marker housing 802 when the stent 100 is in its unexpanded state. This is due to the fact that it is desirable that the tube's natural curvature be utilized. If the stent were in its expanded state, the coining process would change the curvature due to the pressure or force exerted by the coining tool.
  • the marker inserts 804 form a substantially solid line that clearly defines the ends of the stent in the stent delivery system when seen under fluoroscopic equipment.
  • the markers 800 move away from each other and flower open as the stent 100 expands as illustrated in Figure 7.
  • the change in the marker grouping provides the physician or other health care provider with the ability to determine when the stent 100 has been fully deployed from the stent delivery system.
  • markers 800 may be positioned at other locations on the stent 100.
  • Figure 13 illustrates an alternate exemplary embodiment of a radiopaque marker 900.
  • the marker housing 902 comprises flat sides 914 and 916.
  • the flat sides 914 and 916 serve a number of functions. Firstly, the flat sides 914 and 916 minimize the overall profile of the stent 100 without reducing the radiopacity of the stent 100 under x-ray fluoroscopy. Essentially, the flat sides 914 and 916 allow the marker housings 902 to fit more closely together when the stent 100 is crimped for delivery. Accordingly, the flat sides 914 and 916 of the marker housing 902 allow for larger stents to utilize high radiopacity markers while also allowing the stent to fit into smaller delivery systems. For example, the flat sides 914 and 916 on radiopaque markers 900 of the size described above (i.e.
  • the marker insert 904 and the marker hole 906 are formed of the same materials and have the same shape as described above with respect to Figures 1-12.
  • the markers 900 are also constructed utilizing the same coining process as described above.
  • FIG 14 illustrates yet another alternate exemplary embodiment of a radiopaque marker 1000.
  • This exemplary embodiment offers the same advantages as the above-described embodiment; namely, reduced profile without reduction in radiopacity and a reduction in the effects of galvanic corrosion.
  • the radiopaque marker 1000 has substantially the same total area as that of the markers 900, 800 described above, but with an oval shape rather than a circular shape or circular shape with flat sides.
  • the marker 1000 comprises a substantially oval shaped marker housing 1002 and a substantially oval shaped marker insert 1004.
  • the marker 1000 is longer in the axial direction and shorter in the radial direction to allow a larger stent to fit into a smaller delivery system as described above.
  • the nitinol tab to radiopaque marker material ratio is improved.
  • the substantially oval shape provides for a more constant marker housing 1002 thickness around the marker insert 1004.
  • FIG. 10 and 11 show a self-expanding stent delivery apparatus 10 for a stent made in accordance with the present invention.
  • Apparatus 10 comprises inner and outer coaxial tubes.
  • the inner tube is called the shaft 12 and the outer tube is called the sheath 14.
  • Shaft 12 has proximal and distal ends. The proximal end of the shaft 12 terminates at a luer lock hub 16.
  • shaft 12 has a proximal portion 18 which is made from a relatively stiff material such as stainless steel, Nitinol, or any other suitable material, and a distal portion 20 which may be made from a polyethylene, polyimide, Pellethane, Pebax, Vestamid, Cristamid, Grillamid or any other suitable material known to those of ordinary skill in the art.
  • the two portions are joined together by any number of means known to those of ordinary skill in the art.
  • the stainless steel proximal end gives the shaft the necessary rigidity or stiffness it needs to effectively push out the stent, while the polymeric distal portion provides the necessary flexibility to navigate tortuous vessels.
  • the distal portion 20 of the shaft 12 has a distal tip 22 attached thereto.
  • the distal tip 22 has a proximal end 24 whose diameter is substantially the same as the outer diameter of the sheath 14.
  • the distal tip 22 tapers to a smaller diameter from its proximal end to its distal end, wherein the distal end 26 of the distal tip 22 has a diameter smaller than the inner diameter of the sheath 14.
  • a stop 28 which is proximal to the distal tip 22. Stop 28 may be made from any number of materials known in the art, including stainless steel, and is even more preferably made from a highly radiopaque material such as platinum, gold or tantalum.
  • stop 28 is substantially the same as the inner diameter of sheath 14, and would actually make frictional contact with the inner surface of the sheath. Stop 28 helps to push the stent out of the sheath during deployment, and helps keep the stent from migrating proximally into the sheath 14.
  • a stent bed 30 is defined as being that portion of the shaft between the distal tip 22 and the stop 28.
  • the stent bed 30 and the stent 100 are coaxial so that the distal portion 20 of shaft 12 comprising the stent bed 30 is located within the lumen of the stent 100.
  • the stent bed 30 does not make any contact with stent 100 itself.
  • shaft 12 has a guidewire lumen 32 extending along its length from its proximal end and exiting through its distal tip 22. This allows the shaft 12 to receive a guidewire much in the same way that an ordinary balloon angioplasty catheter receives a guidewire.
  • Such guidewires are well known in art and help guide catheters and other medical devices through the vasculature of the body.
  • Sheath 14 is preferably a polymeric catheter and has a proximal end terminating at a sheath hub 40. Sheath 14 also has a distal end which terminates at the proximal end 24 of distal tip 22 of the shaft 12, when the stent is in its fully un-deployed position as shown in the figures.
  • the distal end of sheath 14 includes a radiopaque marker band 34 disposed along its outer surface. As will be explained below, the stent is fully deployed from the delivery apparatus when the marker band 34 is lined up with radiopaque stop 28, thus indicating to the physician that it is now safe to remove the apparatus 10 from the body.
  • Sheath 14 preferably comprises an outer polymeric layer and an inner polymeric layer.
  • Braided reinforcing layer Positioned between outer and inner layers is a braided reinforcing layer. Braided reinforcing layer is preferably made from stainless steel.
  • the use of braided reinforcing layers in other types of medical devices can be found in U.S. Patent No. 3,585,707 issued to Stevens on June 22, 1971, U.S. Patent No. 5,045,072 issued to Castillo et al. on September 3, 1991, and U.S. Patent No. 5,254,107 issued to Soltesz on October 19, 1993.
  • FIGS 10 and 11 illustrate the stent 100 as being in its fully un-deployed position. This is the position the stent is in when the apparatus 10 is inserted into the vasculature and its distal end is navigated to a target site.
  • Stent 100 is disposed around stent bed 30 and at the distal end of sheath 14.
  • the distal tip 22 of the shaft 12 is distal to the distal end of the sheath 14, and the proximal end of the shaft 12 is proximal to the proximal end of the sheath 14.
  • the stent 100 is in a compressed state and makes frictional contact with the inner surface 36 of the sheath 14.
  • a Tuohy Borst valve 38 When being inserted into a patient, sheath 14 and shaft 12 are locked together at their proximal ends by a Tuohy Borst valve 38. This prevents any sliding movement between the shaft and sheath which could result in a premature deployment or partial deployment of the stent 100. When the stent 100 reaches its target site and is ready for deployment, the Tuohy Borst valve 38 is opened so that that the sheath 14 and shaft 12 are no longer locked together.
  • the method under which the apparatus 10 deploys the stent 100 is readily apparent.
  • the apparatus 10 is first inserted into the vessel until the radiopaque stent markers 800 (leading 102 and trailing 104 ends, see Figure 7) are proximal and distal to the target lesion. Once this has occurred the physician would open the Tuohy Borst valve 38. The physician would then grasp hub 16 of shaft 12 so as to hold it in place. Thereafter, the physician would grasp the proximal end of the sheath 14 and slide it proximal, relative to the shaft 12. Stop 28 prevents the stent 100 from sliding back with the sheath 14, so that as the sheath 14 is moved back, the stent 100 is pushed out of the distal end of the sheath 14.
  • the radiopaque stent markers 800 move apart once they come out of the distal end of sheath 14. Stent deployment is complete when the marker 34 on the outer sheath 14 passes the stop 28 on the inner shaft 12. The apparatus 10 can now be withdrawn through the stent 100 and removed from the patient.
  • Figure 12 illustrates the stent 100 in a partially deployed state. As illustrated, as the stent 100 expands from the delivery device 10, the markers 800 move apart from one another and expand in a flower like manner.
  • Nitinol is utilized in a wide variety of applications, including medical device applications as described above. Nitinol or Ni-Ti alloys are widely utilized in the fabrication or construction of medical devices for a number of reasons, including its biomechanical compatibility, its biocompatibility, its fatigue resistance, its kink resistance, its uniform plastic deformation, its magnetic resonance imaging compatibility, its constant and stricte outward pressure, its dynamic interference, its thermal deployment capability, its elastic deployment capability, its hysteresis characteristics and it is modestly radiopaque.
  • Nitinol exhibits shape memory and/or superelastic characteristics. Shape memory characteristics may be simplistically described as follows.
  • a metallic structure for example, a Nitinol tube that is in an Austenite phase may be cooled to a temperature such that it is in the Martensite phase. Once in the Martensite phase, the Nitinol tube may be deformed into a particular configuration or shape by the application of stress. As long as the Nitinol tube is maintained in the Martensite phase, the Nitinol tube will remain in its deformed shape.
  • Nitinol tube If the Nitinol tube is heated to a temperature sufficient to cause the Nitinol tube to reach the Austenite phase, the Nitinol tube will return to its original or programmed shape.
  • the original shape is programmed to be a particular shape by well-known techniques as briefly described above.
  • Superelastic characteristics may be simplistically described as follows.
  • a metallic structure for example, a Nitinol tube that is in an Austenite phase may be deformed to a particular shape or configuration by the application of mechanical energy.
  • the application of mechanical energy causes a stress induced Martensite phase transformation. In other words, the mechanical energy causes the Nitinol tube to transform from the Austenite phase to the Martensite phase.
  • the stress from the mechanical energy causes a temperature drop in the Nitinol tube.
  • the Nitinol tube undergoes another mechanical phase transformation back to the Austenite phase and thus its original or programmed shape.
  • the original shape is programmed by well-known techniques.
  • the Martensite and Austenite phases are common phases in many metals.
  • the Martensite phase is the low temperature phase.
  • a material in the Martensite phase is typically very soft and malleable. These properties make it easier to shape or configure the Nitinol into complicated or complex structures.
  • the Austenite phase is the high temperature phase. A material in the Austenite phase is generally much stronger than the material in the Martensite phase.
  • many medical devices are cooled to the Martensite phase for manipulation and loading into delivery systems, as described above with respect to stents and then when the device is deployed at body temperature, they return to the Austenite phase.
  • the materials described herein may be utilized in substantially any medical device.
  • binary Nitinol and other Nitinol alloys may be utilized in implantable medical devices such as embolic filters and braces.
  • Self-expanding stents are currently made from Ni-Ti alloys in which the phase transformation temperature (Martensite/Austenite) is adjusted so that the stent recovers to its programmed shape at body temperature by a shape memory process or by superelasticity.
  • phase transformation temperature Martensite/Austenite
  • binary Ni-Ti alloys they have lower radiopacities than other materials from which stents are fabricated or constructed, which in turn makes it difficult to image by traditional x-ray techniques. Difficulty in imaging may increase the difficulty in placement of the stent. For this reason many medical devices have affixed thereto coils, wires and or caps formed from high radiopacity materials such as platinum and/or palladium, two transition metals. Alternately, various types of markers such as described above may be particularly advantageous for increasing a devices radiopacity.
  • a material or materials for increasing the radiopacity of the device may be alloyed into the binary Nitinol.
  • the stent illustrated in Figures 1-6 may comprise an alloy of Ni-Ti and any other highly radiopaque material which is compatible with the Ni and Ti as well as being biocompatible.
  • the stent illustrated in Figures 1-6 may comprise Ni-Ti-Pt or Ni-Ti-Pd alloys which, when processed through traditional thermomechanical processing techniques, exhibit shape memory and/or superelastic properties around body temperature.
  • the advantage of a stent fabricated from such an alloy over state of the art binary Ni-Ti alloy described herein is that the platinum or palladium addition increases the radiopacity of the alloy, and thus the stent may not need additional elements such as markers.
  • Pd x or Pt x would be on the order of about five atomic percent to about fifty atomic percent for Ni-Ti (1-x) - Pd x or Ni-Ti (1-x) - Pt x and more preferably Pd x or Pt x from about five atomic percent to about fifteen atomic percent.
  • phase transformation temperature may be changed by altering or manipulating the processing of the alloy.

Abstract

An intraluminal medical device comprising a substantially tubular member having open ends, a first diameter for insertion into a lumen of a vessel and a second diameter for anchoring in the lumen of the vessel. the substantially tubular member comprises an alloy including nickel, titanium and a metal having a radiopacity greater than nickel or titanium.

Description

  • The present invention relates to intraluminal devices, and more particularly to intraluminal devices, such as stents, incorporating integral markers for increasing the radiopacity thereof. The present invention also relates to intraluminal devices formed from higher radiopacity alloys.
  • Percutaneous transluminal angioplasty (PTA) is a therapeutic medical procedure used to increase blood flow through an artery. In this procedure, the angioplasty balloon is inflated within the stenosed vessel, or body passageway, in order to shear and disrupt the wall components of the vessel to obtain an enlarged lumen. With respect to arterial stenosed lesions, the relatively incompressible plaque remains unaltered, while the more elastic medial and adventitial layers of the body passageway stretch around the plaque. This process produces dissection, or a splitting and tearing, of the body passageway wall layers, wherein the intima, or internal surface of the artery or body passageway, suffers fissuring. This dissection forms a "flap" of underlying tissue which may reduce the blood flow through the lumen, or completely block the lumen. Typically, the distending intraluminal pressure within the body passageway can hold the disrupted layer, or flap, in place. If the intimal flap created by the balloon dilation procedure is not maintained in place against the expanded intima, the intimal flap can fold down into the lumen and close off the lumen, or may even become detached and enter the body passageway. When the intimal flap closes off the body passageway, immediate surgery is necessary to correct the problem.
  • Recently, transluminal prostheses have been widely used in the medical arts for implantation in blood vessels, biliary ducts, or other similar organs of the living body. These prostheses are commonly referred to as stents and are used to maintain, open, or dilate tubular structures. An example of a commonly used stent is given in U.S. Patent No. 4,733,665 to Palmaz. Such stents are often referred to as balloon expandable stents. Typically the stent is made from a solid tube of stainless steel. Thereafter, a series of cuts are made in the wall of the stent. The stent has a first smaller diameter which permits the stent to be delivered through the human vasculature by being crimped onto a balloon catheter. The stent also has a second, expanded diameter, upon application of a radially, outwardly directed force, by the balloon catheter, from the interior of the tubular shaped member.
  • However, one concern with such stents is that they are often impractical for use in some vessels such as the carotid artery. The carotid artery is easily accessible from the exterior of the human body, and is close to the surface of the skin. A patient having a balloon expandable stent made from stainless steel or the like, placed in their carotid artery, might be susceptible to severe injury through day to day activity. A sufficient force placed on the patient's neck could cause the stent to collapse, resulting in injury to the patient. In order to prevent this, self-expanding stents have been proposed for use in such vessels.
    Self-expanding stents act like springs and will recover to their expanded or implanted configuration after being crushed.
  • One type of self-expanding stent is disclosed in U.S. Patent No. 4,655,771. The stent disclosed in U.S. Patent No. 4,655,771 has a radially and axially flexible, elastic tubular body with a predetermined diameter that is variable under axial movement of the ends of the body relative to each other and which is composed of a plurality of individually rigid but flexible and elastic thread elements defining a radially self-expanding helix. This type of stent is known in the art as a "braided stent" and is so designated herein. Placement of such stents in a body vessel can be achieved by a device which comprises an outer catheter for holding the stent at its distal end, and an inner piston which pushes the stent forward once it is in position.
  • However, braided stents have many disadvantages. They typically do not have the necessary radial strength to effectively hold open a diseased vessel. In addition, the plurality of wires or fibers used to make such stents could become dangerous if separated from the body of the stent, where they could pierce through the vessel. Therefore, there has been a desire to have a self-expanding stent which is cut from a tube of metal, which is the common manufacturing method for many commercially available balloon-expandable stents. In order to manufacture a self-expanding stent cut from a tube, the alloy used would preferably exhibit superelastic or psuedoelastic characteristics at body temperature, so that it is crush recoverable.
  • The prior art makes reference to the use of alloys such as Nitinol (Ni Ti alloy), which have shape memory and/or superelastic characteristics, in medical devices which are designed to be inserted into a patient's body. The shape memory characteristics allow the devices to be deformed to facilitate their insertion into a body lumen or cavity and then be heated within the body so that the device returns to its original shape. Superelastic characteristics, on the other hand, generally allow the metal to be deformed and restrained in the deformed condition to facilitate the insertion of the medical device containing the metal into a patient's body, with such deformation causing the phase transformation. Once within the body lumen, the restraint on the superelastic member can be removed, thereby reducing the stress therein so that the superelastic member can return to its original un-deformed shape by the transformation back to the original phase.
  • Alloys having shape memory/superelastic characteristics generally have at least two phases. These phases are a martensite phase, which has a relatively low tensile strength and which is stable at relatively low temperatures, and an austenite phase, which has a relatively high tensile strength and which is stable at temperatures higher than the martensite phase.
  • Shape memory characteristics are imparted to the alloy by heating the metal at a temperature above which the transformation from the martensite phase to the austenite phase is complete, i.e. a temperature above which the austenite phase is stable (the Af temperature). The shape of the metal during this heat treatment is the shape "remembered." The heat-treated metal is cooled to a temperature at which the martensite phase is stable, causing the austenite phase to transform to the martensite phase. The metal in the martensite phase is then plastically deformed, e.g. to facilitate the entry thereof into a patient's body. Subsequent heating of the deformed martensite phase to a temperature above the martensite to austenite transformation temperature causes the deformed martensite phase to transform to the austenite phase, and during this phase transformation the metal reverts back to its original shape if unrestrained. If restrained, the metal will remain martensitic until the restraint is removed.
  • Methods of using the shape memory characteristics of these alloys in medical devices intended to be placed within a patient's body present operational difficulties. For example, with shape memory alloys having a stable martensite temperature below body temperature, it is frequently difficult to maintain the temperature of the medical device containing such an alloy sufficiently below body temperature to prevent the transformation of the martensite phase to the austenite phase when the device was being inserted into a patient's body. With intravascular devices formed of shape memory alloys having martensite to austenite transformation temperatures well above body temperature, the devices can be introduced into a patient's body with little or no problem, but they must be heated to the martensite to austenite transformation temperature which is frequently high enough to cause tissue damage.
  • When stress is applied to a specimen of a metal such as Nitinol exhibiting superelastic characteristics at a temperature above which the austenite is stable (i.e. the temperature at which the transformation of martensite phase to the austenite phase is complete), the specimen deforms elastically until it reaches a particular stress level where the alloy then undergoes a stress induced phase transformation from the austenite phase to the martensite phase. As the phase transformation proceeds, the alloy undergoes significant increases in strain but with little or no corresponding increases in stress. The strain increases while the stress remains essentially constant until the transformation of the austenite phase to the martensite phase is complete. Thereafter, further increases in stress are necessary to cause further deformation. The martensitic metal first deforms elastically upon the application of additional stress and then plastically with permanent residual deformation.
  • If the load on the specimen is removed before any permanent deformation has occurred, the martensitic specimen will elastically recover and transform back to the austenite phase. The reduction in stress first causes a decrease in strain. As stress reduction reaches the level at which the martensite phase transforms back into the austenite phase, the stress level in the specimen will remain essentially constant (but substantially less than the constant stress level at which the austenite transforms to the martensite) until the transformation back to the austenite phase is complete, i.e. there is significant recovery in strain with only negligible corresponding stress reduction. After the transformation back to austenite is complete, further stress reduction results in elastic strain reduction. This ability to incur significant strain at relatively constant stress upon the application of a load, and to recover from the deformation upon the removal of the load, is commonly referred to as superelasticity or pseudoelasticity. It is this property of the material which makes it useful in manufacturing tube cut self-expanding stents.
  • The prior art makes reference to the use of metal alloys having superelastic characteristics in medical devices which are intended to be inserted or otherwise used within a patient's body. See for example, U.S. Patent No. 4,665,905 to Jervis and U.S. Patent No. 4,925,445 to Sakamoto et al. However, the prior art has yet to disclose any suitable tube-cut self-expanding stents. In addition, many of the prior art stents lacked the necessary rigidity or hoop strength to keep the body vessel open. In addition, many of the prior art stents have large openings at their expanded diameter. The smaller the openings are on an expanded stent, the more plaque or other deposits it can trap between the stent and the vessel wall. Trapping these deposits is important to the continuing health of the patient in that it helps prevent plaque prolapse into the vessel, restenosis of the vessel it is implanted into, and strokes caused by the release of embolic particles into the bloodstream.
  • One additional concern with stents and with other medical devices formed from superelastic materials, is that they may exhibit reduced radiopacity under X-ray fluoroscopy. To overcome this problem, it is common practice to attach markers, made from highly radiopaque materials, to the stent, or to use radiopaque materials in plating or coating processes. Those materials typically include gold, platinum, or tantalum. The prior art makes reference to these markers or processes in U.S. Patent No. 5,632,771 to Boatman et al., U.S. Patent No. 6,022,374 to Imran, U.S. Patent No. 5,741,327 to Frantzen, U.S. Patent No. 5,725,572 to Lam et al., and U.S. Patent No. 5,800,526 to Anderson et al. However, due to the size of the markers and the relative position of the materials forming the markers in the galvanic series versus the position of the base metal of the stent in the galvanic series, there is a certain challenge to overcome; namely, that of galvanic corrosion. Also, the size of the markers increases the overall profile of the stent. In addition, typical markers are not integral to the stent and thus may interfere with the overall performance of the stent as well as become dislodged from the stent. Also, typical markers are used to indicate relative position within the lumen and not whether the device is in the deployed or undepolyed position.
  • The present invention overcomes many of the disadvantages associated with reduced radiopacity exhibited by self-expanding stents, balloon-expandable stents, and other medical devices as briefly discussed above.
  • In accordance with one aspect, the present invention is directed to an intraluminal medical device. The intraluminal medical device comprises a substantially tubular member having open ends, a first diameter for insertion into a lumen of a vessel and a second diameter for anchoring in the lumen of the vessel. The substantially tubular member comprising an alloy including nickel, titanium and a metal having a radiopacity greater than nickel or titanium.
  • The improved radiopacity intraluminal medical device of the present invention utilizes high radiopacity markers to ensure proper positioning of the device within a lumen. The markers comprise a housing which is integral to the device itself, thereby ensuring minimal interference with deployment and operation of the device. The housings are also shaped to minimally impact the overall profile of the stent. For example, a properly shaped housing allows a stent to maintain a radiopaque stent marker size utilized in a seven French delivery system to fit into a six French delivery system. The markers also comprise a properly sized marker insert having a higher radiopacity than the material forming the device itself. The marker insert is sized to match the curvature of the housing thereby ensuring a tight and unobtrusive fit. The marker inserts are made from a material close in the galvanic series to the device material and sized to substantially minimize the effect of galvanic corrosion.
  • The improved radiopacity intraluminal medical device of the present invention provides for more precise placement and post-procedural visualization in a lumen by increasing the radiopacity of the device under X-ray fluoroscopy. Given that the marker housings are integral to the device, they are simpler and less expensive to manufacture than markers that have to be attached in a separate process.
  • The improved radiopacity intraluminal medical device of the present invention is manufactured utilizing a process which ensures that the marker insert is securely positioned within the marker housing. The marker housing is laser cut from the same tube and is integral to the device. As a result of the laser cutting process, the hole in the marker housing is conical in the radial direction with the outer surface diameter being larger than the inner surface diameter. The conical tapering effect in the marker housing is beneficial in providing an interference fit between the marker insert and the marker housing to prevent the marker insert from being dislodged once the device is deployed. The marker inserts are loaded into a crimped device by punching a disk from annealed ribbon stock and shaping it to have the same radius of curvature as the marker housing. Once the disk is loaded into the marker housing, a coining process is used to properly seat the marker below the surface of the housing. The coining punch is also shaped to maintain the same radius of curvature as the marker housing. The coining process deforms the marker housing material to form a protrusion, thereby locking in the insert or disk.
  • The improved radiopacity intraluminal medical device of the present invention may comprise an alloy of nickel, titanium and other suitable material or materials having higher radiopacities than the nickel and titanium. Two such compatible materials include platinum and palladium. The addition of these materials will increase the radiopacity of the medical device and may reduce the need for additional markers.
  • Embodiments of the invention will now be described by way of example with reference to the accompanying drawings, in which:
  • Figure 1 is a perspective view of an exemplary stent in its compressed state which may be utilized in conjunction with the present invention;
  • Figure 2 is a sectional, flat view of the stent shown in Figure 1;
  • Figure 3 is a perspective view of the stent shown in Figure 1 but showing it in its expanded state;
  • Figure 4 is an enlarged sectional view of the stent shown in Figure 3;
  • Figure 5 is an enlarged view of section of the stent shown in Figure 2;
  • Figure 6 is a view similar to that of Figure 2 but showing an alternate embodiment of the stent;
  • Figure 7 is a perspective view of the stent of Figure 1 having a plurality of markers attached to the ends thereof in accordance with the present invention;
  • Figure 8 is a cross-sectional view of a marker in accordance with the present invention;
  • Figure 9 is an enlarged perspective view of an end of the stent with the markers forming a substantially straight line in accordance with the present invention;
  • Figure 10 is a simplified partial cross-sectional view of a stent delivery apparatus having a stent loaded therein, which can be used with a stent made in accordance with the present invention;
  • Figure 11 is a view similar to that of Figure 10 but showing an enlarged view of the distal end of the apparatus;
  • Figure 12 is a perspective view of an end of the stent with the markers in a partially expanded form as it emerges from the delivery apparatus in accordance with the present invention;
  • Figure 13 is an enlarged perspective view of an end of the stent with modified markers in accordance with an alternate exemplary embodiment of the present invention;
  • Figure 14 is an enlarged perspective view of an end of the stent with modified markers in accordance with another alternate exemplary embodiment of the present invention; and
  • Figure 15 is a phase diagram for a titanium, nickel, palladium alloy and a titanium, nickel, platinum alloy in accordance with the present invention.
  • While the present invention may be used on or in connection with any number of medical devices, including stents, for ease of explanation, one exemplary embodiment of the invention with respect to self-expanding nickel titanium shape-memory alloy stents, such as Nitinol stents will be described in detail. There is illustrated in Figures 1 and 2, a stent 100, which may be utilized in connection with the present invention. Figures 1 and 2 illustrate the exemplary stent 100 in its unexpanded or compressed state. The stent 100 is preferably made from a superelastic alloy such as Nitinol. Most preferably, the stent 100 is made from an alloy comprising from about 50.0 percent (as used herein these percentages refer to weight percentages) Ni to about 60 percent Ni, and more preferably about 55.8 percent Ni, with the remainder of the alloy being Ti. Preferably, the stent 100 is designed such that it is superelastic at body temperature, and preferably has an Af in the range from about twenty-four degrees C to about thirty-seven degrees C. The superelastic design of the stent 100 makes it crush recoverable, which, as discussed above, makes it useful as a stent or frame for any number of vascular devices in different applications.
  • Stent 100 is a tubular member having front and back open ends 102 and 104 and a longitudinal axis 106 extending therebetween. The tubular member has a first smaller diameter, Figures 1 and 2, for insertion into a patient and navigation through the vessels, and a second larger diameter, Figures 3 and 4, for deployment into the target area of a vessel. The tubular member is made from a plurality of adjacent hoops 108, Figure 1 showing hoops 108(a) - 108(d), extending between the front and back ends 102 and 104. The hoops 108 include a plurality of longitudinal struts 110 and a plurality of loops 112 connecting adjacent struts, wherein adjacent struts are connected at opposite ends so as to form a substantially S or Z shape pattern. The loops 112 are curved, substantially semi-circular with symmetrical sections about their centers 114.
  • Stent 100 further includes a plurality of bridges 116 which connect adjacent hoops 108 and which can best be described in detail by referring to Figure 5. Each bridge 116 has two ends 118 and 120. The bridges 116 have one end attached to one strut and/or loop, and another end attached to a strut and/or loop on an adjacent hoop. The bridges 116 connect adjacent struts together at bridge to loop connection points 122 and 124. For example, bridge end 118 is connected to loop 114(a) at bridge to loop connection point 122, and bridge end 120 is connected to loop 114(b) at bridge to loop connection point 124. Each bridge to loop connection point has a center 126. The bridge to loop connection points are separated angularly with respect to the longitudinal axis. That is, the connection points are not immediately opposite each other. Essentially, one could not draw a straight line between the connection points, wherein such line would be parallel to the longitudinal axis of the stent.
  • The above described geometry helps to better distribute strain throughout the stent, prevents metal to metal contact when the stent is bent, and minimizes the opening size between the struts, loops and bridges. The number of and nature of the design of the struts, loops and bridges are important factors when determining the working properties and fatigue life properties of the stent. It was previously thought that in order to improve the rigidity of the stent, that struts should be large, and therefore there should be fewer struts per hoop. However, it has now been discovered that stents having smaller struts and more struts per hoop actually improve the construction of the stent and provide greater rigidity. Preferably, each hoop has between twenty-four to thirty-six or more struts. It has been determined that a stent having a ratio of number of struts per hoop to strut length L (in inches) which is greater than four hundred has increased rigidity over prior art stents, which typically have a ratio of under two hundred. The length of a strut is measured in its compressed state parallel to the longitudinal axis 106 of the stent 100 as illustrated in Figure 1.
  • As seen from a comparison of Figures 2 and 3, the geometry of the stent 100 changes quite significantly as the stent 100 is deployed from its un-expanded state to its expanded state. As a stent undergoes diametric change, the strut angle and strain levels in the loops and bridges are affected. Preferably, all of the stent features will strain in a predictable manor so that the stent is reliable and uniform in strength. In addition, it is preferable to minimize the maximum strain experienced by struts loops and bridges, since Nitinol properties are more generally limited by strain rather than by stress. As will be discussed in greater detail below, the stent sits in the delivery system in its un-expanded state as shown in Figures 10 and 11. As the stent is deployed, it is allowed to expand towards its expanded state, as shown in Figure 3, which preferably has a diameter which is the same or larger than the diameter of the target vessel. Nitinol stents made from wire deploy in much the same manner, and are dependent upon the same design constraints, as laser cut stents. Stainless steel stents deploy similarly in terms of geometric changes as they are assisted by forces from balloons or other devices.
  • In trying to minimize the maximum strain experienced by features of the stent, the present invention utilizes structural geometries which distribute strain to areas of the stent which are less susceptible to failure than others. For example, one of the most vulnerable areas of the stent is the inside radius of the connecting loops. The connecting loops undergo the most deformation of all the stent features. The inside radius of the loop would normally be the area with the highest level of strain on the stent. This area is also critical in that it is usually the smallest radius on the stent. Stress concentrations are generally controlled or minimized by maintaining the largest radii possible. Similarly, we want to minimize local strain concentrations on the bridge and bridge connection points. One way to accomplish this is to utilize the largest possible radii while maintaining feature widths which are consistent with applied forces. Another consideration is to minimize the maximum open area of the stent. Efficient utilization of the original tube from which the stent is cut increases stent strength and its ability to trap embolic material.
  • Many of these design objectives have been accomplished by an exemplary embodiment of the present invention, illustrated in Figures 1, 2 and 5. As seen from these figures, the most compact designs which maintain the largest radii at the loop to bridge connections are non-symmetric with respect to the centerline of the strut connecting loop. That is, loop to bridge connection point centers 126 are offset from the center 114 of the loops 112 to which they are attached. This feature is particularly advantageous for stents having large expansion ratios, which in turn requires them to have extreme bending requirements where large elastic strains are required. Nitinol can withstand extremely large amounts of elastic strain deformation, so the above features are well suited to stents made from this alloy. This feature allows for maximum utilization of Ni-Ti or other material properties to enhance radial strength, to improve stent strength uniformity, to improve fatigue life by minimizing local strain levels, to allow for smaller open areas which enhance entrapment of embolic material, and to improve stent apposition in irregular vessel wall shapes and curves.
  • As seen in Figure 5, stent 100 comprises strut connecting loops 112 having a width W1, as measured at the center 114 parallel to axis 106, which are greater than the strut widths W2, as measured perpendicular to axis 106 itself. In fact, it is preferable that the thickness of the loops vary so that they are thickest near their centers. This increases strain deformation at the strut and reduces the maximum strain levels at the extreme radii of the loop. This reduces the risk of stent failure and allows one to maximize radial strength properties. This feature is particularly advantageous for stents having large expansion ratios, which in turn requires them to have extreme bending requirements where large elastic strains are required. Nitinol can withstand extremely large amounts of elastic strain deformation, so the above features are well suited to stents made from this alloy. As stated above, this feature allows for maximum utilization of Ni-Ti or other material properties to enhance radial strength, to improve stent strength uniformity, to improve fatigue life by minimizing local strain levels, to allow for smaller open areas which enhance entrapment of embolic material, and to improve stent apposition in irregular vessel wall shapes and curves.
  • As mentioned above, bridge geometry changes as a stent is deployed from its compressed state to its expanded state and vise-versa. As a stent undergoes diametric change, strut angle and loop strain is affected. Since the bridges are connected to either the loops, struts or both, they are affected. Twisting of one end of the stent with respect to the other, while loaded in the stent delivery system, should be avoided. Local torque delivered to the bridge ends displaces the bridge geometry. If the bridge design is duplicated around the stent perimeter, this displacement causes rotational shifting of the two loops being connected by the bridges. If the bridge design is duplicated throughout the stent, as in the present invention, this shift will occur down the length of the stent. This is a cumulative effect as one considers rotation of one end with respect to the other upon deployment. A stent delivery system, such as the one described below, will deploy the distal end first, then allow the proximal end to expand. It would be undesirable to allow the distal end to anchor into the vessel wall while holding the stent fixed in rotation, then release the proximal end. This could cause the stent to twist or whip in rotation to equilibrium after it is at least partially deployed within the vessel. Such whipping action may cause damage to the vessel.
  • However, one exemplary embodiment of the present invention, as illustrated in Figures 1 and 2, reduces the chance of such events happening when deploying the stent. By mirroring the bridge geometry longitudinally down the stent, the rotational shift of the Z-sections or S-sections may be made to alternate and will minimize large rotational changes between any two points on a given stent during deployment or constraint. That is, the bridges 116 connecting loop 108(b) to loop 108(c) are angled upwardly from left to right, while the bridges connecting loop 108(c) to loop 108(d) are angled downwardly from left to right. This alternating pattern is repeated down the length of the stent 100. This alternating pattern of bridge slopes improves the torsional characteristics of the stent so as to minimize any twisting or rotation of the stent with respect to any two hoops. This alternating bridge slope is particularly beneficial if the stent starts to twist in vivo. As the stent twists, the diameter of the stent will change. Alternating bridge slopes tend to minimize this effect. The diameter of a stent having bridges which are all sloped in the same direction will tend to grow if twisted in one direction and shrink if twisted in the other direction. With alternating bridge slopes this effect is minimized and localized.
  • The feature is particularly advantageous for stents having large expansion ratios, which in turn requires them to have extreme bending requirements where large elastic strains are required. Nitinol, as stated above, can withstand extremely large amounts of elastic strain deformation, so the above features are well suited to stents made from this alloy. This feature allows for maximum utilization of Ni-Ti or other material properties to enhance radial strength, to improve stent strength uniformity, to improve fatigue life by minimizing local strain levels, to allow for smaller open areas which enhance entrapment of embolic material, and to improve stent apposition in irregular vessel wall shapes and curves.
  • Preferably, stents are laser cut from small diameter tubing. For prior art stents, this manufacturing process led to designs with geometric features, such as struts, loops and bridges, having axial widths W2, W1 and W3, respectively, which are larger than the tube wall thickness T (illustrated in Figure 3). When the stent is compressed, most of the bending occurs in the plane that is created if one were to cut longitudinally down the stent and flatten it out. However, for the individual bridges, loops and struts, which have widths greater than their thickness, there is a greater resistance to this in-plane bending than to out-of-plane bending. Because of this, the bridges and struts tend to twist, so that the stent as a whole may bend more easily. This twisting is a buckling condition which is unpredictable and can cause potentially high strain.
  • However, this problem has been solved in an exemplary embodiment of the present invention, as illustrated in Figures 1-5. As seen from these figures, the widths of the struts, hoops and bridges are equal to or less than the wall thickness of the tube. Therefore, substantially all bending and, therefore, all strains are "out-of-plane." This minimizes twisting of the stent which minimizes or eliminates buckling and unpredictable strain conditions. This feature is particularly advantageous for stents having large expansion ratios, which in turn requires them to have extreme bending requirements where large elastic strains are required. Nitinol, as stated above, can withstand extremely large amounts of elastic strain deformation, so the above features are well suited to stents made from this alloy. This feature allows for maximum utilization of Ni-Ti or other material properties to enhance radial strength, to improve stent strength uniformity, to improve fatigue life by minimizing local strain levels, to allow for smaller open areas which enhance entrapment of embolic material, and to improve stent apposition in irregular vessel wall shapes and curves.
  • An alternate exemplary embodiment of a stent that may be utilized in conjunction with the present invention is illustrated in Figure 6. Figure 6 shows stent 200 which is similar to stent 100 illustrated in Figures 1-5. Stent 200 is made from a plurality of adjacent hoops 202, Figure 6 showing hoops 202(a) - 202(d). The hoops 202 include a plurality of longitudinal struts 204 and a plurality of loops 206 connecting adjacent struts, wherein adjacent struts are connected at opposite ends so as to form a substantially S or Z shape pattern. Stent 200 further includes a plurality of bridges 208 which connect adjacent hoops 202. As seen from the figure, bridges 208 are non-linear and curve between adjacent hoops. Having curved bridges allows the bridges to curve around the loops and struts so that the hoops can be placed closer together which in turn, minimizes the maximum open area of the stent and increases its radial strength as well. This can best be explained by referring to Figure 4. The above described stent geometry attempts to minimize the largest circle which could be inscribed between the bridges, loops and struts, when the stent is expanded. Minimizing the size of this theoretical circle, greatly improves the stent because it is then better suited to trap embolic material once it is inserted into the patient.
  • As mentioned above, it is preferred that the stent of the present invention be made from a superelastic alloy and most preferably made of an alloy material having greater than 50.5 atomic percentage Nickel and the balance Titanium. Greater than 50.5 atomic percentage Nickel allows for an alloy in which the temperature at which the martensite phase transforms completely to the austenite phase (the Af temperature) is below human body temperature, and preferably is about twenty-four degrees C to about thirty-seven degrees C, so that austenite is the only stable phase at body temperature.
  • In manufacturing the Nitinol stent, the material is first in the form of a tube. Nitinol tubing is commercially available from a number of suppliers including Nitinol Devices and Components, Fremont CA. The tubular member is then loaded into a machine which will cut the predetermined pattern of the stent into the tube, as discussed above and as shown in the figures. Machines for cutting patterns in tubular devices to make stents or the like are well known to those of ordinary skill in the art and are commercially available. Such machines typically hold the metal tube between the open ends while a cutting laser, preferably under microprocessor control, cuts the pattern. The pattern dimensions and styles, laser positioning requirements, and other information are programmed into a microprocessor which controls all aspects of the process. After the stent pattern is cut, the stent is treated and polished using any number of methods or combination of methods well known to those skilled in the art. Lastly, the stent is then cooled until it is completely martensitic, crimped down to its un-expanded diameter and then loaded into the sheath of the delivery apparatus.
  • As stated in previous sections of this application, markers having a radiopacity greater than that of the superelastic alloys may be utilized to facilitate more precise placement of the stent within the vasculature. In addition, markers may be utilized to determine when and if a stent is fully deployed. For example, by determining the spacing between the markers, one can determine if the deployed stent has achieved its maximum diameter and adjusted accordingly utilizing a tacking process. Figure 7 illustrates an exemplary embodiment of the stent 100 illustrated in Figures 1-5 having at least one marker on each end thereof. In a preferred embodiment, a stent having thirty-six struts per hoop can accommodate six markers 800. Each marker 800 comprises a marker housing 802 and a marker insert 804. The marker insert 804 may be formed from any suitable biocompatible material having a high radiopacity under X-ray fluoroscopy. In other words, the marker inserts 804 should preferably have a radiopacity higher than that of the material comprising the stent 100. The addition of the marker housings 802 to the stent necessitates that the lengths of the struts in the last two hoops at each end of the stent 100 be longer than the strut lengths in the body of the stent to increase the fatigue life at the stent ends. The marker housings 802 are preferably cut from the same tube as the stent as briefly described above. Accordingly, the housings 802 are integral to the stent 100. Having the housings 802 integral to the stent 100 serves to ensure that the markers 800 do not interfere with the operation of the stent
  • Figure 8 is a cross-sectional view of a marker housing 802. The housing 802 may be elliptical when observed from the outer surface as illustrated in Figure 7. As a result of the laser cutting process, the hole 806 in the marker housing 802 is conical in the radial direction with the outer surface 808 having a diameter larger than the diameter of the inner surface 810, as illustrated in Figure 8. The conical tapering in the marker housing 802 is beneficial in providing an interference fit between the marker insert 804 and the marker housing 802 to prevent the marker insert 804 from being dislodged once the stent 100 is deployed. A detailed description of the process of locking the marker insert 804 into the marker housing 802 is given below.
  • As set forth above, the marker inserts 804 may be made from any suitable material having a radiopacity higher than the superelastic material forming the stent or other medical device. For example, the marker insert 804 may be formed from niobium, tungsten, gold, platinum or tantalum. In the preferred embodiment, tantalum is utilized because of its closeness to nickel-titanium in the galvanic series and thus would minimize galvanic corrosion. In addition, the surface area ratio of the tantalum marker inserts 804 to the nickel-titanium is optimized to provide the largest possible tantalum marker insert, easy to see, while minimizing the galvanic corrosion potential. For example, it has been determined that up to nine marker inserts 804 having a diameter of 0.254 mm (0.010 inches) could be placed at the end of the stent 100; however, these marker inserts 804 would be less visible under X-ray fluoroscopy. On the other hand, three to four marker inserts 804 having a diameter of 0.635 mm (0.025 inches) could be accommodated on the stent 100; however, galvanic corrosion resistance would be compromised. Accordingly, in the preferred embodiment, six tantalum markers having a diameter of 0.508 mm (0.020 inches) are utilized on each end of the stent 100 for a total of twelve markers 800.
  • The tantalum markers 804 may be manufactured and loaded into the housing utilizing a variety of known techniques. In the exemplary embodiment, the tantalum markers 804 are punched out from an annealed ribbon stock and are shaped to have the same curvature as the radius of the marker housing 802 as illustrated in Figure 8. Once the tantalum marker insert 804 is loaded into the marker housing 802, a coining process is used to properly seat the marker insert 804 below the surface of the housing 802. The coining punch is also shaped to maintain the same radius of curvature as the marker housing 802. As illustrated in Figure 8, the coining process deforms the marker housing 802 material to lock in the marker insert 804.
  • As stated above, the hole 806 in the marker housing 802 is conical in the radial direction with the outer surface 808 having a diameter larger than the diameter of the inner surface 810 as illustrated in Figure 8. The inside and outside diameters vary depending on the radius of the tube from which the stent is cut. The marker inserts 804, as stated above, are formed by punching a tantalum disk from annealed ribbon stock and shaping it to have the same radius of curvature as the marker housing 802. It is important to note that the marker inserts 804, prior to positioning in the marker housing 804, have straight edges. In other words, they are not angled to match the hole 806. The diameter of the marker insert 804 is between the inside and outside diameter of the marker housing 802. Once the marker insert 804 is loaded into the marker housing 802, a coining process is used to properly seat the marker insert 804 below the surface of the marker housing 802. In the preferred embodiment, the thickness of the marker insert 804 is less than or equal to the thickness of the tubing and thus the thickness or height of the hole 806. Accordingly, by applying the proper pressure during the coining process and using a coining tool that is larger than the marker insert 804, the marker insert 804 may be seated in the marker housing 802 in such a way that it is locked into position by a radially oriented protrusion 812. Essentially, the applied pressure, and size and shape of the housing tool forces the marker insert 804 to form the protrusion 812 in the marker housing 802. The coining tool is also shaped to maintain the same radius of curvature as the marker housing 802. As illustrated in Figure 8, the protrusion 812 prevents the marker insert 804 from becoming dislodged from the marker housing 802.
  • It is important to note that the marker inserts 804 are positioned in and locked into the marker housing 802 when the stent 100 is in its unexpanded state. This is due to the fact that it is desirable that the tube's natural curvature be utilized. If the stent were in its expanded state, the coining process would change the curvature due to the pressure or force exerted by the coining tool.
  • As illustrated in Figure 9, the marker inserts 804 form a substantially solid line that clearly defines the ends of the stent in the stent delivery system when seen under fluoroscopic equipment. As the stent 100 is deployed from the stent delivery system, the markers 800 move away from each other and flower open as the stent 100 expands as illustrated in Figure 7. The change in the marker grouping provides the physician or other health care provider with the ability to determine when the stent 100 has been fully deployed from the stent delivery system.
  • It is important to note that the markers 800 may be positioned at other locations on the stent 100.
  • Figure 13 illustrates an alternate exemplary embodiment of a radiopaque marker 900. In this exemplary embodiment, the marker housing 902 comprises flat sides 914 and 916.
  • The flat sides 914 and 916 serve a number of functions. Firstly, the flat sides 914 and 916 minimize the overall profile of the stent 100 without reducing the radiopacity of the stent 100 under x-ray fluoroscopy. Essentially, the flat sides 914 and 916 allow the marker housings 902 to fit more closely together when the stent 100 is crimped for delivery. Accordingly, the flat sides 914 and 916 of the marker housing 902 allow for larger stents to utilize high radiopacity markers while also allowing the stent to fit into smaller delivery systems. For example, the flat sides 914 and 916 on radiopaque markers 900 of the size described above (i.e. having appropriately sized markers) allow a stent to maintain a radiopaque stent marker size utilized in a seven French delivery system to fit into a six French delivery system. Secondly, the flat sides 914 and 916 also maximize the nitinol tab to radiopaque marker material ratio, thereby further reducing the effects of any galvanic corrosion as described above. The marker insert 904 and the marker hole 906 are formed of the same materials and have the same shape as described above with respect to Figures 1-12. The markers 900 are also constructed utilizing the same coining process as described above.
  • Figure 14 illustrates yet another alternate exemplary embodiment of a radiopaque marker 1000. This exemplary embodiment offers the same advantages as the above-described embodiment; namely, reduced profile without reduction in radiopacity and a reduction in the effects of galvanic corrosion. In this exemplary embodiment, the radiopaque marker 1000 has substantially the same total area as that of the markers 900, 800 described above, but with an oval shape rather than a circular shape or circular shape with flat sides. As illustrated, the marker 1000 comprises a substantially oval shaped marker housing 1002 and a substantially oval shaped marker insert 1004. Essentially, in this exemplary embodiment, the marker 1000 is longer in the axial direction and shorter in the radial direction to allow a larger stent to fit into a smaller delivery system as described above. Also as in the above-described exemplary embodiment, the nitinol tab to radiopaque marker material ratio is improved. In addition, the substantially oval shape provides for a more constant marker housing 1002 thickness around the marker insert 1004. Once again, the markers 1000 are constructed from the same materials and are constructed utilizing the same coining process as described above.
  • It is believed that many of the advantages of the present invention can be better understood through a brief description of a delivery apparatus for the stent, as shown in Figures 10 and 11. Figures 10 and 11 show a self-expanding stent delivery apparatus 10 for a stent made in accordance with the present invention. Apparatus 10 comprises inner and outer coaxial tubes. The inner tube is called the shaft 12 and the outer tube is called the sheath 14. Shaft 12 has proximal and distal ends. The proximal end of the shaft 12 terminates at a luer lock hub 16. Preferably, shaft 12 has a proximal portion 18 which is made from a relatively stiff material such as stainless steel, Nitinol, or any other suitable material, and a distal portion 20 which may be made from a polyethylene, polyimide, Pellethane, Pebax, Vestamid, Cristamid, Grillamid or any other suitable material known to those of ordinary skill in the art. The two portions are joined together by any number of means known to those of ordinary skill in the art. The stainless steel proximal end gives the shaft the necessary rigidity or stiffness it needs to effectively push out the stent, while the polymeric distal portion provides the necessary flexibility to navigate tortuous vessels.
  • The distal portion 20 of the shaft 12 has a distal tip 22 attached thereto. The distal tip 22 has a proximal end 24 whose diameter is substantially the same as the outer diameter of the sheath 14. The distal tip 22 tapers to a smaller diameter from its proximal end to its distal end, wherein the distal end 26 of the distal tip 22 has a diameter smaller than the inner diameter of the sheath 14. Also attached to the distal portion 20 of shaft 12 is a stop 28 which is proximal to the distal tip 22. Stop 28 may be made from any number of materials known in the art, including stainless steel, and is even more preferably made from a highly radiopaque material such as platinum, gold or tantalum. The diameter of stop 28 is substantially the same as the inner diameter of sheath 14, and would actually make frictional contact with the inner surface of the sheath. Stop 28 helps to push the stent out of the sheath during deployment, and helps keep the stent from migrating proximally into the sheath 14.
  • A stent bed 30 is defined as being that portion of the shaft between the distal tip 22 and the stop 28. The stent bed 30 and the stent 100 are coaxial so that the distal portion 20 of shaft 12 comprising the stent bed 30 is located within the lumen of the stent 100. However, the stent bed 30 does not make any contact with stent 100 itself. Lastly, shaft 12 has a guidewire lumen 32 extending along its length from its proximal end and exiting through its distal tip 22. This allows the shaft 12 to receive a guidewire much in the same way that an ordinary balloon angioplasty catheter receives a guidewire. Such guidewires are well known in art and help guide catheters and other medical devices through the vasculature of the body.
  • Sheath 14 is preferably a polymeric catheter and has a proximal end terminating at a sheath hub 40. Sheath 14 also has a distal end which terminates at the proximal end 24 of distal tip 22 of the shaft 12, when the stent is in its fully un-deployed position as shown in the figures. The distal end of sheath 14 includes a radiopaque marker band 34 disposed along its outer surface. As will be explained below, the stent is fully deployed from the delivery apparatus when the marker band 34 is lined up with radiopaque stop 28, thus indicating to the physician that it is now safe to remove the apparatus 10 from the body. Sheath 14 preferably comprises an outer polymeric layer and an inner polymeric layer. Positioned between outer and inner layers is a braided reinforcing layer. Braided reinforcing layer is preferably made from stainless steel. The use of braided reinforcing layers in other types of medical devices can be found in U.S. Patent No. 3,585,707 issued to Stevens on June 22, 1971, U.S. Patent No. 5,045,072 issued to Castillo et al. on September 3, 1991, and U.S. Patent No. 5,254,107 issued to Soltesz on October 19, 1993.
  • Figures 10 and 11 illustrate the stent 100 as being in its fully un-deployed position. This is the position the stent is in when the apparatus 10 is inserted into the vasculature and its distal end is navigated to a target site. Stent 100 is disposed around stent bed 30 and at the distal end of sheath 14. The distal tip 22 of the shaft 12 is distal to the distal end of the sheath 14, and the proximal end of the shaft 12 is proximal to the proximal end of the sheath 14. The stent 100 is in a compressed state and makes frictional contact with the inner surface 36 of the sheath 14.
  • When being inserted into a patient, sheath 14 and shaft 12 are locked together at their proximal ends by a Tuohy Borst valve 38. This prevents any sliding movement between the shaft and sheath which could result in a premature deployment or partial deployment of the stent 100. When the stent 100 reaches its target site and is ready for deployment, the Tuohy Borst valve 38 is opened so that that the sheath 14 and shaft 12 are no longer locked together.
  • The method under which the apparatus 10 deploys the stent 100 is readily apparent. The apparatus 10 is first inserted into the vessel until the radiopaque stent markers 800 (leading 102 and trailing 104 ends, see Figure 7) are proximal and distal to the target lesion. Once this has occurred the physician would open the Tuohy Borst valve 38. The physician would then grasp hub 16 of shaft 12 so as to hold it in place. Thereafter, the physician would grasp the proximal end of the sheath 14 and slide it proximal, relative to the shaft 12. Stop 28 prevents the stent 100 from sliding back with the sheath 14, so that as the sheath 14 is moved back, the stent 100 is pushed out of the distal end of the sheath 14. As stent 100 is being deployed the radiopaque stent markers 800 move apart once they come out of the distal end of sheath 14. Stent deployment is complete when the marker 34 on the outer sheath 14 passes the stop 28 on the inner shaft 12. The apparatus 10 can now be withdrawn through the stent 100 and removed from the patient.
  • Figure 12 illustrates the stent 100 in a partially deployed state. As illustrated, as the stent 100 expands from the delivery device 10, the markers 800 move apart from one another and expand in a flower like manner.
  • Nitinol is utilized in a wide variety of applications, including medical device applications as described above. Nitinol or Ni-Ti alloys are widely utilized in the fabrication or construction of medical devices for a number of reasons, including its biomechanical compatibility, its biocompatibility, its fatigue resistance, its kink resistance, its uniform plastic deformation, its magnetic resonance imaging compatibility, its constant and gentile outward pressure, its dynamic interference, its thermal deployment capability, its elastic deployment capability, its hysteresis characteristics and it is modestly radiopaque.
  • Nitinol, as described above, exhibits shape memory and/or superelastic characteristics. Shape memory characteristics may be simplistically described as follows. A metallic structure, for example, a Nitinol tube that is in an Austenite phase may be cooled to a temperature such that it is in the Martensite phase. Once in the Martensite phase, the Nitinol tube may be deformed into a particular configuration or shape by the application of stress. As long as the Nitinol tube is maintained in the Martensite phase, the Nitinol tube will remain in its deformed shape. If the Nitinol tube is heated to a temperature sufficient to cause the Nitinol tube to reach the Austenite phase, the Nitinol tube will return to its original or programmed shape. The original shape is programmed to be a particular shape by well-known techniques as briefly described above. Superelastic characteristics may be simplistically described as follows. A metallic structure, for example, a Nitinol tube that is in an Austenite phase may be deformed to a particular shape or configuration by the application of mechanical energy. The application of mechanical energy causes a stress induced Martensite phase transformation. In other words, the mechanical energy causes the Nitinol tube to transform from the Austenite phase to the Martensite phase. By utilizing the appropriate measuring instruments, one can determine that the stress from the mechanical energy causes a temperature drop in the Nitinol tube. Once the mechanical energy or stress is released, the Nitinol tube undergoes another mechanical phase transformation back to the Austenite phase and thus its original or programmed shape. As described above, the original shape is programmed by well-known techniques. The Martensite and Austenite phases are common phases in many metals.
  • Medical devices constructed from Nitinol are typically utilized in both the Martensite phase and/or the Austenite phase. The Martensite phase is the low temperature phase. A material in the Martensite phase is typically very soft and malleable. These properties make it easier to shape or configure the Nitinol into complicated or complex structures. The Austenite phase is the high temperature phase. A material in the Austenite phase is generally much stronger than the material in the Martensite phase. Typically, many medical devices are cooled to the Martensite phase for manipulation and loading into delivery systems, as described above with respect to stents and then when the device is deployed at body temperature, they return to the Austenite phase.
  • It is important to note that although the exemplary embodiments described herein are related to stents, the materials described herein may be utilized in substantially any medical device. For example, binary Nitinol and other Nitinol alloys may be utilized in implantable medical devices such as embolic filters and braces.
  • Self-expanding stents are currently made from Ni-Ti alloys in which the phase transformation temperature (Martensite/Austenite) is adjusted so that the stent recovers to its programmed shape at body temperature by a shape memory process or by superelasticity. However, a minor problem as described above, with binary Ni-Ti alloys is that they have lower radiopacities than other materials from which stents are fabricated or constructed, which in turn makes it difficult to image by traditional x-ray techniques. Difficulty in imaging may increase the difficulty in placement of the stent. For this reason many medical devices have affixed thereto coils, wires and or caps formed from high radiopacity materials such as platinum and/or palladium, two transition metals. Alternately, various types of markers such as described above may be particularly advantageous for increasing a devices radiopacity.
  • In an alternate exemplary embodiment, a material or materials for increasing the radiopacity of the device may be alloyed into the binary Nitinol. For example, the stent illustrated in Figures 1-6 may comprise an alloy of Ni-Ti and any other highly radiopaque material which is compatible with the Ni and Ti as well as being biocompatible. The stent illustrated in Figures 1-6 may comprise Ni-Ti-Pt or Ni-Ti-Pd alloys which, when processed through traditional thermomechanical processing techniques, exhibit shape memory and/or superelastic properties around body temperature. The advantage of a stent fabricated from such an alloy over state of the art binary Ni-Ti alloy described herein is that the platinum or palladium addition increases the radiopacity of the alloy, and thus the stent may not need additional elements such as markers.
  • Typical alloy addition, Pdx or Ptx , would be on the order of about five atomic percent to about fifty atomic percent for Ni-Ti (1-x)- Pdx or Ni-Ti (1-x)- Ptx and more preferably Pdx or Ptx from about five atomic percent to about fifteen atomic percent.
  • Referring to Figure 15, there is illustrated a phase diagram for Ti50 (Ni (50-x) Pdx) and Ti50 (Ni (50-x) Ptx). As illustrated, for Pdx or Ptx, where x is in the range from about five atomic percent to about fifteen atomic percent, the Martensite start temperature, Ms, is relatively low. Although the addition of Pt or Pd increases the phase transformation temperature, the phase transformation temperature may be changed by altering or manipulating the processing of the alloy.
  • The present invention is not restricted to the particular constructions described and illustrated, but should be constructed to cohere with all modifications that may fall within the scope of the appended claims.

Claims (7)

  1. An intraluminal medical device comprising a substantially tubular member having open ends, a first diameter for insertion into a lumen of a vessel and a second diameter for anchoring in the lumen of the vessel, the substantially tubular member comprising an alloy including nickel, titanium and a metal having a radiopacity greater than nickel or titanium.
  2. The intraluminal medical device according to Claim 1, wherein the intraluminal medical device comprises an alloy having superelastic and shape memory characteristics.
  3. The intraluminal medical device according to Claim 2, wherein the alloy comprises nickel, titanium and platinum.
  4. The intraluminal medical device according to Claim 2, wherein the alloy comprises nickel, titanium and palladium.
  5. The intraluminal medical device according to Claim 3, wherein the alloy comprises Ti50 (Ni(50-x) Ptx) where x ranges from about five to fifteen atomic percent.
  6. The intraluminal medical device according to Claim 4, wherein the alloy comprises Ti50 (Ni (50-x) Pdx), where x ranges from about five to fifteen atomic percent.
  7. The intraluminal medical device according to Claim 2, wherein the substantially tubular member comprises a stent.
EP04252955A 2003-05-20 2004-05-20 Enhanced radiopacity intraluminal device Withdrawn EP1479358A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US47199803P 2003-05-20 2003-05-20
US471998P 2003-05-20
US10/844,108 US20040236409A1 (en) 2003-05-20 2004-05-12 Radiopacity intraluminal medical device
US844108P 2004-05-12

Publications (1)

Publication Number Publication Date
EP1479358A1 true EP1479358A1 (en) 2004-11-24

Family

ID=33457300

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04252955A Withdrawn EP1479358A1 (en) 2003-05-20 2004-05-20 Enhanced radiopacity intraluminal device

Country Status (4)

Country Link
US (1) US20040236409A1 (en)
EP (1) EP1479358A1 (en)
JP (1) JP5020461B2 (en)
CA (1) CA2467940C (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006007231A1 (en) * 2006-02-15 2007-08-30 "Stiftung Caesar" (Center Of Advanced European Studies And Research) Method of wrapping a stent
US7658760B2 (en) 2000-12-28 2010-02-09 Abbott Cardiovascular Systems Inc. Thermoelastic and superelastic Ni-Ti-W alloy
US9999527B2 (en) 2015-02-11 2018-06-19 Abbott Cardiovascular Systems Inc. Scaffolds having radiopaque markers
US10070975B2 (en) 2006-01-04 2018-09-11 Abbott Cardiovascular Systems Inc. Stents with radiopaque markers
US10610387B2 (en) 2015-06-12 2020-04-07 Abbott Cardiovascular Systems Inc. Scaffolds having a radiopaque marker and methods for attaching a marker to a scaffold

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7686846B2 (en) 1996-06-06 2010-03-30 Devax, Inc. Bifurcation stent and method of positioning in a body lumen
US8728143B2 (en) 1996-06-06 2014-05-20 Biosensors International Group, Ltd. Endoprosthesis deployment system for treating vascular bifurcations
GB0020491D0 (en) 2000-08-18 2000-10-11 Angiomed Ag Stent with attached element and method of making such a stent
EP1567087B1 (en) 2002-11-08 2009-04-01 Jacques Seguin Endoprosthesis for vascular bifurcation
GB0609841D0 (en) 2006-05-17 2006-06-28 Angiomed Ag Bend-capable tubular prosthesis
GB0609911D0 (en) * 2006-05-18 2006-06-28 Angiomed Ag Bend-capable stent prosthesis
GB0613670D0 (en) * 2006-07-10 2006-08-16 Angiomed Ag Tubular metal prosthesis and method of making it
GB0616729D0 (en) * 2006-08-23 2006-10-04 Angiomed Ag Method of welding a component to a shape memory alloy workpiece
GB0616999D0 (en) * 2006-08-29 2006-10-04 Angiomed Ag Annular mesh
EP2059619B1 (en) * 2006-09-06 2010-11-17 Cook Incorporated Nickel-titanium alloy including a rare earth element
EP2063824B1 (en) * 2006-09-07 2020-10-28 Angiomed GmbH & Co. Medizintechnik KG Helical implant having different ends
GB0622465D0 (en) 2006-11-10 2006-12-20 Angiomed Ag Stent
GB0624419D0 (en) * 2006-12-06 2007-01-17 Angiomed Ag Stenting ring with marker
GB0703379D0 (en) * 2007-02-21 2007-03-28 Angiomed Ag Stent with radiopaque marker
US20080243069A1 (en) * 2007-04-02 2008-10-02 Medtronic Vascular, Inc. Self-Crimping Radiopaque marker
GB0706499D0 (en) 2007-04-03 2007-05-09 Angiomed Ag Bendable stent
US8500786B2 (en) * 2007-05-15 2013-08-06 Abbott Laboratories Radiopaque markers comprising binary alloys of titanium
US8500787B2 (en) * 2007-05-15 2013-08-06 Abbott Laboratories Radiopaque markers and medical devices comprising binary alloys of titanium
GB0717481D0 (en) 2007-09-07 2007-10-17 Angiomed Ag Self-expansible stent with radiopaque markers
WO2009085757A2 (en) 2007-12-21 2009-07-09 Cook Incorporated Radiopaque alloy and medical device made of this alloy
US8187396B2 (en) 2008-06-12 2012-05-29 Cook Medical Technologies Llc Method of making a self-expanding stent
GB2475340B (en) 2009-11-17 2013-03-27 Univ Limerick Nickel-titanium alloy and method of processing the alloy
US8808353B2 (en) 2010-01-30 2014-08-19 Abbott Cardiovascular Systems Inc. Crush recoverable polymer scaffolds having a low crossing profile
US8568471B2 (en) 2010-01-30 2013-10-29 Abbott Cardiovascular Systems Inc. Crush recoverable polymer scaffolds
US9345602B2 (en) 2010-09-23 2016-05-24 Abbott Cardiovascular Systems Inc. Processes for making crush recoverable polymer scaffolds
US8726483B2 (en) 2011-07-29 2014-05-20 Abbott Cardiovascular Systems Inc. Methods for uniform crimping and deployment of a polymer scaffold
GB2495772B (en) 2011-10-21 2014-02-12 Univ Limerick Method of forming a sintered nickel-titanium-rare earth (Ni-Ti-RE) alloy
WO2013109846A1 (en) 2012-01-18 2013-07-25 Cook Medical Technologies Llc Mixture of powders for preparing a sintered nickel-titanium-rare earth metal (ni-ti-re) alloy
WO2013133127A1 (en) * 2012-03-08 2013-09-12 テルモ株式会社 Stent
US8968387B2 (en) 2012-07-23 2015-03-03 Abbott Cardiovascular Systems Inc. Shape memory bioresorbable polymer peripheral scaffolds
US10292845B2 (en) 2013-05-07 2019-05-21 Kaneka Corporation Stent, method for producing same and device for producing same
EP3998100A1 (en) 2014-01-15 2022-05-18 Tufts Medical Center, Inc. Endovascular cerebrospinal fluid shunt system
GB201411486D0 (en) * 2014-06-27 2014-08-13 Isis Innovation Apparatus for providing and maintaining access to a surgical site
CN107148293B (en) 2014-10-31 2020-08-11 西瑞维斯克有限责任公司 Methods and systems for treating hydrocephalus
US9737368B2 (en) 2015-02-24 2017-08-22 Abbott Cardiovascular Systems Inc. System and method for attaching a radiopaque marker bead to an endoprosthesis
US9968472B2 (en) * 2015-10-27 2018-05-15 Contego Medical, Llc Transluminal angioplasty devices and methods of use
CN108136164B (en) 2015-10-30 2020-12-08 西瑞维斯克公司 Systems and methods for treating hydrocephalus
US11013900B2 (en) 2018-03-08 2021-05-25 CereVasc, Inc. Systems and methods for minimally invasive drug delivery to a subarachnoid space
US11179255B2 (en) 2018-03-29 2021-11-23 Sahajanand Medical Technologies Limited Medical devices

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4655771A (en) 1982-04-30 1987-04-07 Shepherd Patents S.A. Prosthesis comprising an expansible or contractile tubular body
US4665905A (en) 1986-06-09 1987-05-19 Brown Charles S Dynamic elbow and knee extension brace
US4733665A (en) 1985-11-07 1988-03-29 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4925445A (en) 1983-09-16 1990-05-15 Fuji Terumo Co., Ltd. Guide wire for catheter
US5632771A (en) 1993-07-23 1997-05-27 Cook Incorporated Flexible stent having a pattern formed from a sheet of material
US5725572A (en) 1994-04-25 1998-03-10 Advanced Cardiovascular Systems, Inc. Radiopaque stent
US5741327A (en) 1997-05-06 1998-04-21 Global Therapeutics, Inc. Surgical stent featuring radiopaque markers
US6022374A (en) 1997-12-16 2000-02-08 Cardiovasc, Inc. Expandable stent having radiopaque marker and method
WO2001039695A2 (en) * 1999-12-01 2001-06-07 Advanced Cardiovascular Systems, Inc. Nitinol alloy composition for vascular stents
US20010039449A1 (en) * 2000-01-24 2001-11-08 A. David Johnson Thin-film shape memory alloy device and method
US20010049549A1 (en) * 2000-06-02 2001-12-06 Boylan John F. Marker device for rotationally orienting a stent delivery system prior to deploying a curved self-expanding stent
US6334871B1 (en) * 1996-03-13 2002-01-01 Medtronic, Inc. Radiopaque stent markers
US20020082681A1 (en) * 2000-12-27 2002-06-27 Boylan John F. Radiopaque nitinol alloys for medical devices

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002026281A1 (en) * 2000-09-29 2002-04-04 Cordis Corporation Coated medical devices

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4655771B1 (en) 1982-04-30 1996-09-10 Medinvent Ams Sa Prosthesis comprising an expansible or contractile tubular body
US4655771A (en) 1982-04-30 1987-04-07 Shepherd Patents S.A. Prosthesis comprising an expansible or contractile tubular body
US4925445A (en) 1983-09-16 1990-05-15 Fuji Terumo Co., Ltd. Guide wire for catheter
US4733665A (en) 1985-11-07 1988-03-29 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4733665B1 (en) 1985-11-07 1994-01-11 Expandable Grafts Partnership Expandable intraluminal graft,and method and apparatus for implanting an expandable intraluminal graft
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US4665905A (en) 1986-06-09 1987-05-19 Brown Charles S Dynamic elbow and knee extension brace
US5632771A (en) 1993-07-23 1997-05-27 Cook Incorporated Flexible stent having a pattern formed from a sheet of material
US5725572A (en) 1994-04-25 1998-03-10 Advanced Cardiovascular Systems, Inc. Radiopaque stent
US6334871B1 (en) * 1996-03-13 2002-01-01 Medtronic, Inc. Radiopaque stent markers
US5741327A (en) 1997-05-06 1998-04-21 Global Therapeutics, Inc. Surgical stent featuring radiopaque markers
US6022374A (en) 1997-12-16 2000-02-08 Cardiovasc, Inc. Expandable stent having radiopaque marker and method
WO2001039695A2 (en) * 1999-12-01 2001-06-07 Advanced Cardiovascular Systems, Inc. Nitinol alloy composition for vascular stents
US20010039449A1 (en) * 2000-01-24 2001-11-08 A. David Johnson Thin-film shape memory alloy device and method
US20010049549A1 (en) * 2000-06-02 2001-12-06 Boylan John F. Marker device for rotationally orienting a stent delivery system prior to deploying a curved self-expanding stent
US20020082681A1 (en) * 2000-12-27 2002-06-27 Boylan John F. Radiopaque nitinol alloys for medical devices

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658760B2 (en) 2000-12-28 2010-02-09 Abbott Cardiovascular Systems Inc. Thermoelastic and superelastic Ni-Ti-W alloy
US8382819B2 (en) 2000-12-28 2013-02-26 Abbot Cardiovascular Systems Inc. Thermoelastic and superelastic Ni-Ti-W alloy
US8702790B2 (en) 2000-12-28 2014-04-22 Abbott Cardiovascular Systems Inc. Thermoelastic and superelastic Ni—Ti—W alloy
US8974517B2 (en) 2000-12-28 2015-03-10 Abbott Cardiovascular Systems Inc. Thermoelastic and superelastic NI-TI-W alloy
US10070975B2 (en) 2006-01-04 2018-09-11 Abbott Cardiovascular Systems Inc. Stents with radiopaque markers
DE102006007231A1 (en) * 2006-02-15 2007-08-30 "Stiftung Caesar" (Center Of Advanced European Studies And Research) Method of wrapping a stent
WO2007093423A3 (en) * 2006-02-15 2008-05-29 Acandis Gmbh & Co Kg Method for coating a stent
DE102006007231B4 (en) * 2006-02-15 2009-04-09 Acandis Gmbh & Co. Kg Method of wrapping a stent
US9999527B2 (en) 2015-02-11 2018-06-19 Abbott Cardiovascular Systems Inc. Scaffolds having radiopaque markers
US10610387B2 (en) 2015-06-12 2020-04-07 Abbott Cardiovascular Systems Inc. Scaffolds having a radiopaque marker and methods for attaching a marker to a scaffold
US11478370B2 (en) 2015-06-12 2022-10-25 Abbott Cardiovascular Systems Inc. Scaffolds having a radiopaque marker and methods for attaching a marker to a scaffold

Also Published As

Publication number Publication date
CA2467940A1 (en) 2004-11-20
JP2004358242A (en) 2004-12-24
JP5020461B2 (en) 2012-09-05
US20040236409A1 (en) 2004-11-25
CA2467940C (en) 2013-10-15

Similar Documents

Publication Publication Date Title
CA2467940C (en) Improved radiopacity intraluminal medical device
CA2442327C (en) Radiopaque intraluminal medical device
CA2426332C (en) Low profile improved radiopacity intraluminal medical device
EP1212991B1 (en) An intravascular device with improved radiopacity
EP1523960B1 (en) Stent design having stent segments which uncouple upon deployment
US6129755A (en) Intravascular stent having an improved strut configuration
AU2002303157A1 (en) Radiopaque intraluminal medical device
EP1025812A1 (en) An intravascular stent having tapered struts
EP0928606A1 (en) An intravascular stent having curved bridges for connecting adjacent hoops
CA2459506C (en) Anvil bridge stent design
CA2459516C (en) Split-bridge stent design

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK

RIN1 Information on inventor provided before grant (corrected)

Inventor name: DUERIG, THOMAS

Inventor name: PELTON, ALAN

17P Request for examination filed

Effective date: 20050512

AKX Designation fees paid

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20061128

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070411